Lymphotoxin and TNF: How it all began-A tribute to the travelers

Cytokine and Growth Factor Reviews

Volumn 25, Issue 2, 2014, Pages 83-89

  Ruddle, Nancy H ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Byron H. Waksman; Lloyd Old; Lymphotoxin; Secondary lymphoid organs; Tertiary lymphoid organs; The Wizard of Oz; Therapeutic inhibitors of LT and TNF; Tumor necrosis factor

Indexed keywords

CYTOKINE ANTIBODY; ETANERCEPT; HYBRID PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA RECEPTOR; MLTA 3698 A; PATECLIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

HUMAN; IN VIVO STUDY; LYMPHOID ORGAN; MEDICAL LITERATURE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; SECONDARY LYMPHOID ORGAN; SHORT SURVEY; TERTIARY LYMPHOID ORGAN; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; LYMPHOID TISSUE; METABOLISM; MOUSE; RAT; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LYMPHOID TISSUE; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; MICE; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84899067681     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.02.001     Document Type: Short Survey

References (82)

1. Baum L.F. The wonderful wizard of Oz 1900, George M Hill Co., Chicago.
2. Spies T., et al. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A 1986, 83(22):8699-8702.
3. Androlewicz M.J., Browning J.L., Ware C.F. Lymphotoxin is expressed as a heteromeric complex with a distinct 33kDa glycoprotein on the surface of an activated human T cell hybridoma. J Biol Chem 1992, 267(4):2542-2547.
4. Young J., et al. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51(1):78-86.
5. Laskov R., et al. Production of tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) by murine pre-B and B cell lymphomas. J Immunol 1990, 144(9):3424-3430.
6. Mebius R.E., Rennert, Weissman Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997, 7(4):493-504.
7. Granger G.A., Williams Lymphocyte cytotoxicity in vitro: activation and release of a cytotoxic factor. Nature 1968, 218(5148):1253-1254.
8. Ruddle N.H., Waksman Cytotoxic effect of lymphocyte-antigen interaction in delayed hypersensitivity. Science 1967, 157(3792):1060-1062.
9. Ruddle N.H., Waksman Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism. J Exp Med 1968, 128(6):1267-1279.
10. Williams T.W., Granger Lymphocyte in vitro cytotoxicity: lymphotoxins of several mammalian species. Nature 1968, 219(5158):1076-1077.
11. Aggarwal B.B., Moffat B., Harkins R.N. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984, 259(1):686-691.
12. Gray P.W., et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984, 312(5996):721-724.
13. Li C.B., et al. Cloning and expression of murine lymphotoxin cDNA. J Immunol 1987, 138(12):4496-4501.
14. Gray P.W., et al. The murine tumor necrosis factor-beta (lymphotoxin) gene sequence. Nucleic Acids Res 1987, 15(9):3937.
15. Banner D.W., et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73(3):431-445.
16. Shalaby M.R., et al. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985, 135(3):2069-2073.
17. Ruddle N.H. A new name for lymphotoxin. J Immunol 1986, 136(6):2335-2336.
18. Browning J.L., et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993, 72(6):847-856.
19. Koni P.A., et al. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6(4):491-500.
20. Carswell E.A., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72(9):3666-3670.
21. Pennica D., et al. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A 1985, 82(18):6060-6064.
22. Gray P.W., et al. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A 1990, 87(19):7380-7384.
23. Beutler B., et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316(6028):552-554.
24. Engelmann H., et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989, 264(20):11974-11980.
25. Loetscher H., et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990, 61(2):351-359.
26. Dembic Z., et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990, 2(4):231-237.
27. Crowe P.D., et al. A lymphotoxin-beta-specific receptor. Science 1994, 264(5159):707-710.
28. Schmid D.S., et al. Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymphokine Res 1987, 6(3):195-202.
29. Schmid D.S., Tite, Ruddle DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant. Proc Natl Acad Sci U S A 1986, 83(6):1881-1885.
30. Sheehan K.C., Ruddle N.H., Schreiber R.D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors J Immunol 11 1989, 142:3884-3893.
31. Picarella D.E., et al. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. J Immunol 1993, 150(9):4136-4150.
32. Picarella D.E., et al. Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas. Proc Natl Acad Sci U S A 1992, 89(21):10036-10040.
33. Cuff C.A., et al. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 1998, 161(12):6853-6860.
34. Madge L.A., Pober TNF signaling in vascular endothelial cells E. Exp Mol Pathol 2001, 70(3):317-325.
35. Kratz A., et al. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996, 183(4):1461-1472.
36. Guerder S., et al. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A 1994, 91(11):5138-5142.
37. De Togni P., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994, 264(5159):703-707.
38. Liepinsh D.J., et al. Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. Mol Cell Biol 2006, 26(11):4214-4225.
39. Ying X., et al. Lymphotoxin plays a crucial role in the development and function of nasal-associated lymphoid tissue through regulation of chemokines and peripheral node addressin. Am J Pathol 2005, 166(1):135-146.
40. Soderberg K.A., et al. MAdCAM-1 expressing sacral lymph node in the lymphotoxin beta-deficient mouse provides a site for immune generation following vaginal herpes simplex virus-2 infection. J Immunol 2004, 173(3):1908-1913.
41. Kruglov A.A., et al. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science 2013, 342(6163):1243-1246.
42. Pasparakis M., et al. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996, 184(4):1397-1411.
43. Akirav E.M., Ruddle N.H., Herold K.C. The role of AIRE in human autoimmune disease. Nat Rev Endocrinol 2011, 7(1):25-33.
44. Ngo V.N., et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999, 189(2):403-412.
45. Browning J.L., et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 2005, 23(5):539-550.
46. Drayton D.L., et al. I kappa B kinase complex alpha kinase activity controls chemokine and high endothelial venule gene expression in lymph nodes and nasal-associated lymphoid tissue. J Immunol 2004, 173(10):6161-6168.
47. Drayton D.L., et al. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006, 7(4):344-353.
48. Drayton D.L., et al. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med 2003, 197(9):1153-1163.
49. Martinet L., Garrido I., Girard J.P. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology 2012, 1(5):789-790.
50. Stranford S., Ruddle N.H. Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: parallels with lymph node stroma. Front Immunol 2012, 3:350.
51. Ruddle N.H. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest 2014, 124(3). in press.
52. Hemmerich S., et al. Sulfation of L-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes. Immunity 2001, 15(2):237-247.
53. Bentley K.L., et al. A yeast-based recombinogenic targeting toolset for transgenic analysis of human disease genes. Ann N Y Acad Sci 2010, 1207:E58-E68.
54. Liao S., et al. Transgenic LacZ under control of Hec-6st regulatory sequences recapitulates endogenous gene expression on high endothelial venules. Proc Natl Acad Sci U S A 2007, 104(11):4577-4582.
55. Bentley K.L. High endothelial venule reporter mice to probe regulation of lymph node vasculature. Adv Exp Med Biol 2011, 691:35-54.
56. Truman L.A., et al. ProxTom lymphatic vessel reporter mice reveal Prox1 expression in the adrenal medulla, megakaryocytes, and platelets. Am J Pathol 2012, 180(4):1715-1725.
57. Truman L.A., et al. Lymphatic vessel function in head and neck inflammation. Lymphat Res Biol 2013, 11(3):187-192.
58. Angeli V., et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006, 24(2):203-215.
59. Liao S., Ruddle Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006, 177(5):3369-3379.
60. Liao S., et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A 2011, 108(46):18784-18789.
61. Knight D.M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30(16):1443-1453.
62. Siegel S.A., et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995, 7(1):15-25.
63. Ware C.F. Protein therapeutics targeted at the TNF superfamily. Adv Pharmacol 2013, 66:51-80.
64. van Hensbroek M.B., et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996, 174(5):1091-1097.
65. Ruddle N.H., et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990, 172(4):1193-1200.
66. Santambrogio L., et al. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol 1993, 151(2):1116-1127.
67. Brennan F.M., et al. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun, 2. Suppl 1989, 177-186.
68. Elliott M.J., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344(8930):1105-1110.
69. Neregard P., et al. Etanercept decreases synovial expression of tumour necrosis factor-alpha and lymphotoxin-alpha in rheumatoid arthritis. Scand J Rheumatol 2013.
70. Fava R.A., et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003, 171(1):115-126.
71. Rennert P.D., et al. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J Exp Med 1996, 184(5):1999-2006.
72. Fava R.A., et al. LTBR-pathway in Sjogren's syndrome: CXCL13 levels and B-cell-enriched ectopic lymphoid aggregates in NOD mouse lacrimal glands are dependent on LTBR. Adv Exp Med Biol 2011, 691:383-390.
73. Fava R.A., et al. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjogren's syndrome. Arthritis Res Ther,. 13(6): p. R 2011, 182.
74. Browning J.L. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008, 223:202-220.
75. Chiang E.Y., et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15(7):766-773.
76. Emu B., et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin alpha: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther 2012, 14(1):R6.
77. Arnason B.G., Jankovic B.D., Waksman B.H. Effect of thymectomy on 'delayed' hypersensitive reactions. Nature 1962, 194:99-100.
78. Arnason B.G., et al. Role of the thymus in immune reactions in rats. II. Suppressive effect of thymectomy at birth on reactions of delayed (cellular) hypersensitivity and the circulating small lymphocyte. J Exp Med 1962, 116:177-186.
79. Jankovic B.D., Waksman B.H., Arnason Role of the thymus in immune ractions in rats. I. The immunologic response to bovine serum albumin (antibody formation, Arthus reactivity, and delayed hypersensitivity) in rats thymectomized or splenectomized at various times after birth. J Exp Med 1962, 116:159-176.
80. Waksman B.H., Arnason B.G., Jankovic B.D. Role of the thymus in immune reactions in rats. III. Changes in the lymphoid organs of thymectomized rats. J Exp Med 1962, 116:187-206.
81. Gery I., Waksman B.H. Role of the thymus in tolerance. V. Suppressive effect of treatment with nonaggregated and aggregated bovine gamma-globulin on specific immune responses in normal adult rats. J Immunol 1967, 98(3):446-460.
82. Gery I., Gershon R.K., Waksman B.H. Potentiation of cultured mouse thymocyte responses by factors released by peripheral leucocytes. J Immunol 1971, 107(6):1778-1780.